证券代码：002437 证券简称：誉衡药业 公告编号：2020-103 哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 2020 年第三季度报告 2020 年 10 月 第 1 页 哈尔滨誉衡药业股份有限公司 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王东绪、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证季度报告中财务报 表的真实、准确、完整。 第 2 页 哈尔滨誉衡药业股份有限公司 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,073,168,429.83 | | 6,407,579,736.43 | -20.83% | | 归属于上市公司股东的净资产（元） | 2,081 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2020-093 哈尔滨誉衡药业股份有限公司 2020 年半年度报告 2020 年 08 月 第 1 页 哈尔滨誉衡药业股份有限公司 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假记载、误导性 陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人王东绪、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证本半年度报告中财 务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本公司风险因素详见"第四节 经营情况讨论与分析——十、公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 第 2 页 | 目录 | | --- | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 | | 第三节 公司业务概要 9 | | 第四节 经营情况讨论与分析 12 | | 第五节 重要事项 22 | | 第六节 股份变动及股东情况 31 | | 第七节 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2020-050 哈尔滨誉衡药业股份有限公司 2020 年第一季度报告 2020 年 04 月 第 1 页 哈尔滨誉衡药业股份有限公司 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证季度报告中财务报 表的真实、准确、完整。 第 2 页 哈尔滨誉衡药业股份有限公司 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 581,019,881.02 | 1,259,190,816.65 | -53.86% | | 归属于上市公司股东的净利润（元） | 658,600,268.54 | 8 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2019-079 哈尔滨誉衡药业股份有限公司 2019 年第三季度报告 2019 年 10 月 第 1 页 哈尔滨誉衡药业股份有限公司 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证季度报告中财务报 表的真实、准确、完整。 第 2 页 哈尔滨誉衡药业股份有限公司 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 9,605,508,714.32 | | 9,477,173,262.97 | 1.35% | | 归属于上市公司股东的净资产（元） | 4,620,6 ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 2,734,204,476.88, representing a 7.77% increase compared to CNY 2,537,094,408.10 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 232,281,100.76, up by 2.81% from CNY 225,936,011.68 in the previous year[18]. - The net cash flow from operating activities was CNY 437,180,511.99, reflecting an 8.20% increase from CNY 404,061,781.12 in the same period last year[18]. - The basic earnings per share for the reporting period was CNY 0.1057, a 2.82% increase compared to CNY 0.1028 in the previous year[18]. - Total assets at the end of the reporting period were CNY 9,537,805,452.70, a 0.64% increase from CNY 9,477,173,262.97 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.91% to CNY 4,536,176,411.46 from CNY 4,324,011,225.63 at the end of the previous year[18]. - The company achieved operating revenue of 2.734 billion RMB, a year-on-year increase of 7.77%[42]. - Net profit attributable to shareholders reached 232 million RMB, up 2.81% compared to the same period last year[36]. - Operating cash flow net amount was 437 million RMB, reflecting an 8.20% increase year-on-year[42]. - The total revenue for the reporting period reached ¥2,734,204,476.88, representing a year-on-year increase of 7.77% compared to ¥2,537,094,408.10 in the same period last year[44]. Assets and Liabilities - Cash and cash equivalents increased by 229.57% to approximately 174 million RMB, influenced by the combined effects of operating, investing, and financing activities[42]. - Total assets increased to CNY 9,537,805,452.70 from CNY 9,477,173,262.97, reflecting a growth of 0.64%[114]. - Current liabilities rose to CNY 4,366,099,310.01 from CNY 4,017,634,432.94, an increase of 8.67%[115]. - Non-current liabilities decreased significantly from CNY 1,065,728,802.08 to CNY 563,558,192.93, a reduction of 47.10%[116]. - Total liabilities decreased to CNY 4,929,657,502.94 from CNY 5,083,363,235.02, a decline of 3.02%[116]. - Owner's equity increased to CNY 4,608,147,949.76 from CNY 4,393,810,027.95, representing a growth of 4.87%[116]. Revenue Sources - The pharmaceutical manufacturing segment generated ¥2,231,405,368.34, accounting for 81.61% of total revenue, with an 8.39% increase from the previous year[44]. - Sales contribution from chronic disease oral products exceeded 50%, with significant growth in specific products: calcium zinc gluconate oral solution increased over 17% and potassium chloride sustained-release tablets grew over 40%[37]. - Domestic sales accounted for 99.88% of total revenue, amounting to ¥2,730,961,421.27, with a growth of 7.75% year-on-year[44]. Research and Development - Research and development investment decreased by 35.93% to approximately 56 million RMB, primarily due to the exclusion of certain biopharmaceutical R&D costs from consolidation[42]. - The company is advancing clinical research for its PD-1 monoclonal antibody, aiming for product registration application within the year and has enrolled over 300 safety evaluation subjects[38]. Market Strategy and Competitiveness - The company aims to strengthen its core competitiveness by focusing on "products, customers, and sales teams" while expanding its market reach[33]. - The company has established a sales network through acquisitions and partnerships, enhancing its market presence and competitiveness[32]. - The marketing strategy focuses on "integrating resources and sinking to the terminal," leading to stable growth in contributions from secondary hospitals and county-level markets[39]. Risks and Challenges - The company faced risks and has outlined measures to address them in the report[5]. - The company faces industry policy risks that may lead to a decline in product sales due to ongoing regulatory changes in the healthcare sector[55]. - There is a risk of goodwill impairment due to multiple acquisitions, which could impact the company's financial performance if the acquired companies do not meet expected earnings[56]. - The company is committed to managing drug development risks by closely following clinical trial policies and implementing effective risk mitigation strategies[57]. - The company emphasizes strict adherence to operational standards to mitigate production and operational risks related to product quality and safety[58]. Shareholder Information - The total number of shares is 2,198,122,950, with 98.94% being unrestricted shares[91]. - The number of restricted shares decreased by 2,739,394 during the reporting period, resulting in a total of 8,423,738 restricted shares at the end of the period[94]. - Harbin Yuheng Group Co., Ltd. held 42.30% of shares, totaling 929,789,325 shares, which are frozen[97]. - YU HENG INTERNATIONAL INVESTMENTS CORPORATION decreased its holdings by 43,959,977 shares, now holding 372,535,027 shares, representing 16.95%[97]. Corporate Governance - The company has not faced any significant media scrutiny or regulatory penalties during the reporting period[65]. - The actual controller and major shareholder of the company, Yuheng International, had their shares judicially frozen due to asset preservation requests from certain stock pledgees[67]. - A total of 12.37 million shares held by Yuheng International were put up for public auction due to debt default, but the auction failed as there were no bids[68]. - The company has no stock incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period[69]. Related Party Transactions - The company reported a daily related party transaction amount of 402.55 million yuan, which is 0.15% of the same type of transactions[71]. - There were no asset or equity acquisition or sale related party transactions during the reporting period[72]. - The company did not engage in any joint external investment related party transactions during the reporting period[73]. - There were no related party debt and credit transactions during the reporting period[74]. - The company has no other significant related party transactions during the reporting period[75]. Guarantees and Commitments - The company has provided guarantees totaling 16.99 million yuan for Yuheng Hong Kong, with a guarantee period of 2 years[80]. - The company has a total of 35 million yuan in guarantees for asset pool business, with a guarantee period of 1 year[80]. - The total approved guarantee amount for subsidiaries during the reporting period was CNY 77,000 million, with actual guarantees amounting to CNY 47,247.14 million[81]. - The total approved guarantee amount at the end of the reporting period was CNY 187,000 million, with actual guarantee balance of CNY 20,994.26 million[81]. Compliance and Accounting - The company’s financial reports are prepared in accordance with the Chinese Accounting Standards, ensuring a true and complete reflection of its financial status[159]. - The company maintains a continuous operating capability for at least 12 months following the reporting period[157]. - The company recognizes cash and cash equivalents as cash on hand and deposits that are readily available for payment[169]. - The company consolidates financial statements based on control, including all subsidiaries under its control in the consolidated financial statements[165].

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2019-053 哈尔滨誉衡药业股份有限公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨誉衡药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"2019 年黑龙江省上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投 资者集体接待日活动，时间为 2019 年 6 月 19 日（周三）14:00 至 16:30。 届时公司董事、董事会秘书王禹先生、财务副总监兼总经理助理纪作哲先生 将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融资情 况和可持续发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实 时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 哈尔滨誉衡 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2019-025 哈尔滨誉衡药业股份有限公司 2018 年年度报告 2019 年 04 月 第 1 页 哈尔滨誉衡药业股份有限公司 致股东 无论是抗肿瘤生物药的推进还是慢病大健康的落地，都会遇到各种繁琐的细节、未知的问题。这些问题的解决，有赖于 更合理、有效的制度支持。所以，2019 年，誉衡将重点完善激励机制，吸引、保留优秀的人才，调动、发挥员工的积极性， 为后续可持续发展奠定基础。 经过 1 年多的检验，誉衡的管理团队交出了一份满意的答卷：公司的资产、业务与控股股东的投资做到了有效隔离，公 司不会对控股股东的债务承担责任；公司核心管理团队稳定，各子公司总经理恪尽职守、无一人离职；公司与上下游合作伙 伴、银行进行坦诚、充分的沟通，确保日常业务、融资项目正常开展。2018 年，公司实现营业收入 54.81 亿元，经营活动产 生的净现金流 11.57 亿元，运营情况稳定。 誉衡能平稳地渡过 2018 年，离不开广大股东、商业伙伴、监管机构、管理团队和 2000 余名员工的关心、支持和帮助。 在此，谨代表本人及公司向大家致以最诚挚的 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2018-137 哈尔滨誉衡药业股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证季度报告中财务报 表的真实、准确、完整。 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 9,361,465,317.36 | | 9,064,144,464.19 | 3.28% | | 归属于上市公司股东的净资产（元） | 4,466,520,494.73 | | 4,173,917,408.23 | 7.01% | | | 本报告期 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2018-107 哈尔滨誉衡药业股份有限公司 2018 年半年度报告 2018 年 08 月 第 1 页 哈尔滨誉衡药业股份有限公司 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假记载、误导性 陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明：保证本半年度报告中财 务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本公司请投资者认真阅读本半年度报告全文，并特别注意以下风险因素。详见"第四节 经营情况讨论与分析——十、 公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 第 2 页 | 目录 | | --- | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 | | 第三节 公司业务概要 9 | | 第四节 经营情况讨论与分析 11 | | 第五节 重要事项 20 | | ...